Zogenix, Inc. (ZGNX) is a pharmaceutical company focused on developing and commercializing therapies for central nervous system disorders. The company's lead product candidate is Fintepla (ZX008), a low-dose fenfluramine for the treatment of Dravet syndrome, a rare and catastrophic form of epilepsy. Zogenix received FDA approval for Fintepla in June 2020, and the drug is currently being marketed in the United States.
In addition to Fintepla, Zogenix is developing MT1621, an investigational drug for the treatment of TK2 deficiency, a rare genetic mitochondrial disease. The company is also evaluating other early-stage pipeline programs.
Zogenix was founded in 2006 and is headquartered in Emeryville, California.
Zogenix, Inc. (ZGNX) is a pharmaceutical company focused on developing and commercializing therapies for central nervous system disorders. The company's lead product candidate is Fintepla (ZX008), a low-dose fenfluramine for the treatment of Dravet syndrome, a rare and catastrophic form of epilepsy. Zogenix received FDA approval for Fintepla in June 2020, and the drug is currently being marketed in the United States.